The estimated Net Worth of Mark J Rosenblum is at least $676 Thousand dollars as of 31 May 2022. Mr. Rosenblum owns over 28,000 units of Salarius Pharmaceuticals stock worth over $237,310 and over the last 14 years he sold SLRX stock worth over $0. In addition, he makes $438,287 as Chief Financial Officer and Executive Vice President - Finance at Salarius Pharmaceuticals.
Mark has made over 6 trades of the Salarius Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 28,000 units of SLRX stock worth $5,040 on 31 May 2022.
The largest trade he's ever made was buying 76,246 units of Salarius Pharmaceuticals stock on 3 March 2022 worth over $29,736. On average, Mark trades about 4,933 units every 121 days since 2010. As of 31 May 2022 he still owns at least 148,319 units of Salarius Pharmaceuticals stock.
You can see the complete history of Mr. Rosenblum stock trades at the bottom of the page.
Mark J. Rosenblum serves as Chief Financial Officer, Executive Vice President - Finance of the Company. Mr. Rosenblum has served as our Executive Vice President Finance and Chief Financial Officer since September 2019. Prior to September 2019, Mr. Rosenblum served as a financial consultant to Private Salarius since February 2019, to assist in the Merger. Prior to joining Private Salarius, Mr. Rosenblum served as chairman, chief executive officer and a director of ActiveCare, Inc. (Nasdaq: ACAR), a healthcare company, from December 2017 to March 2019. Mr. Rosenblum worked as a financial consultant for various companies from 2014 to 2017. Prior to that, Mr. Rosenblum served as the chief financial officer of Advaxis, Inc. (Nasdaq: ADXS), a biotechnology company, from January 2010 to April 2014. From 1985 through 2003, Mr. Rosenblum was employed by Wellman, Inc., a global public chemical manufacturer, which was subsequently acquired by DAK Americas, serving in various capacities including chief accounting officer. Mr. Rosenblum holds both a Masters in Accountancy and a B.S. degree in Accounting from the University of South Carolina. Mr. Rosenblum began his career in 1977 with Haskins & Sells, CPA (currently known as Deloitte), was a licensed Certified Public Accountant for over 30 years, and is currently a member of the American Institute of Certified Public Accountants.
As the Chief Financial Officer and Executive Vice President - Finance of Salarius Pharmaceuticals, the total compensation of Mark Rosenblum at Salarius Pharmaceuticals is $438,287. There are 3 executives at Salarius Pharmaceuticals getting paid more, with William McVicar having the highest compensation of $1,160,520.
Mark Rosenblum is 66, he's been the Chief Financial Officer and Executive Vice President - Finance of Salarius Pharmaceuticals since 2019. There are 2 older and 6 younger executives at Salarius Pharmaceuticals. The oldest executive at Salarius Pharmaceuticals, Inc. is Arnold Hanish, 72, who is the Independent Director.
Mark's mailing address filed with the SEC is C/O SALARIUS PHARMACEUTICALS, INC., 2450 HOLCOMBE BLVD., SUITE X, HOUSTON, TX, 77021.
Over the last 5 years, insiders at Salarius Pharmaceuticals have traded over $0 worth of Salarius Pharmaceuticals stock and bought 487,662 units worth $209,636 . The most active insiders traders include David J. Arthur, Mark J Rosenblum, and Arnold C Hanish. On average, Salarius Pharmaceuticals executives and independent directors trade stock every 40 days with the average trade being worth of $33,925. The most recent stock trade was executed by Tess Burleson on 7 June 2022, trading 27,700 units of SLRX stock currently worth $4,986.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and potential biomarkers for Seclidemstat (SP-2577). Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Salarius Pharmaceuticals executives and other stock owners filed with the SEC include: